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ABSTRACT
....................................................................................................................................................
Electronic reporting of genetic testing results is increasing, but they are often represented in diverse formats and naming
conventions. Logical Observation Identifiers Names and Codes (LOINC) is a vocabulary standard that provides universal
identifiers for laboratory tests and clinical observations. In genetics, LOINC provides codes to improve interoperability in
the midst of reporting style transition, including codes for cytogenetic or mutation analysis tests, specific chromosomal
alteration or mutation testing, and fully structured discrete genetic test reporting. LOINC terms follow the recommenda-
tions and nomenclature of other standards such as the Human Genome Organization Gene Nomenclature Committee’s
terminology for gene names. In addition to the narrative text they report now, we recommend that laboratories always
report as discrete variables chromosome analysis results, genetic variation(s) found, and genetic variation(s) tested for.
By adopting and implementing data standards like LOINC, information systems can help care providers and researchers
unlock the potential of genetic information for delivering more personalized care.
....................................................................................................................................................
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INTRODUCTION
Strong arguments exist for delivering molecular genetic test
results to electronic health records (EHRs) as standards-based,
structured (computable) electronic reports for clinical and
research purposes.1–4 The fact that most genetic tests apply
for a lifetime and may have to be automatically reinterpreted as
new knowledge becomes available3 only strengthens these ar-
guments. Logical Observation Identifiers Names and Codes
(LOINC; Regenstrief Institute Inc, Indianapolis, IN) and HL7
(Health Level Seven International, Ann Arbor, MI) are the main-
stays for structured reporting of routine laboratory test results.5
These 2 key standards also provide a framework for structured
reporting of genomic tests6 in conjunction with widely accepted
vocabulary standards for naming genes and genetic varia-
tions.3,7–9 In this report, we will describe LOINC’s approach to
naming/coding genetic tests (and their results), its scope, its
mechanisms for gathering new content, and its current
limitations.
LOINC
LOINC is a universal code system developed by the Regenstrief
Institute for identifying laboratory tests and clinical observations
in electronic messaging.10 The current release14 contains more
than 73 000 terms, covering the full scope of laboratory testing
(chemistry, microbiology, etc) and a broad range of clinical
measurements (eg, vital signs, electrocardiograms, patient
reported outcomes, clinical document titles,11,12 and radiology
reports13,14). LOINC includes a data model for representing
answer lists, panels of individual observations, other details
like help text, and units of measure.15 New versions of the
standard are published twice yearly. LOINC has been widely
adopted as the standard for laboratory test result names in the
United States, where it is a national standard,16,17 and interna-
tionally.18,19 Many genetic test reporting initiatives,20,21 includ-
ing the HL7 Clinical Genomics Working Group,22,23 have
adopted LOINC.
Here we focus on the 1400+ LOINC terms currently used in
human genetic test reporting. Documentation and downloads
of the entire LOINC database are available at http://loinc.org.
Naming conventions in LOINC
Each LOINC term has a fully specified name containing 6 main
axes (Component/Analyte, Property, Timing, System/Specimen,
and Method). The axes produce names detailed enough to dis-
tinguish among similar observations.18 For naming genetic
tests that target specific genetic variations, LOINC uses the
Human Genome Organization Gene Nomenclature Committee’s
terminology24 to name the gene(s) and the Human Genome
Variation Society’s (HGVS) syntax to name the variation(s)25 of
interest. We are aware of the challenges due to misnaming and
version changes in these nomenclatures26; however, the thou-
sands of LOINC users tend to detect and report such problems.
Updates to LOINC terms follow best practices.27 Where updates
do not alter the meaning, we correct “wrong” portions of the
name and keep the old names as synonyms. Alternatively, a
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new term can be created and the old term retired, adding a
forward link to the new term.
Scope of LOINC coverage
LOINC provides codes for a broad range of human molecular
genetic and cytogenetic tests. Here we provide a sampling
of the LOINC content so that laboratories will be better able to -
understand and use LOINC terms for ordering and reporting.
Many laboratories report the “simpler” genetic tests as individ-
ual and computer-understandable HL7 Version 2
observations in a way similar to the reporting of routine chem-
istry and hematology tests. These simpler kinds of genetic tests
are the ones most commonly ordered in primary care,28 and
LOINC has observation codes available for most of them.
Tests for specific gene mutations
As of July 2014, LOINC carries 192 terms for reporting single
mutations (variants) qualitatively as present or absent, eg, HFE
gene.p.C282Y [21695-2]—the variation most commonly asso-
ciated with hereditary hemochromatosis in Caucasians. It also
carries a quantitative measure of single mutations, eg, JAK2
p.V617F mutant/control [53761-3]—a report on the prevalence
of white cells with the variation associated with polycythemia
vera. Both of these examples use HGVS nomenclature as part
of the test name. The National Center for Biotechnology
Information’s (NCBI) Single Nucleotide Polymorphism database
(dbSNP) codes29 may also be embedded in LOINC test names,
especially when the variation is outside of the coding region,
eg, IL28B gene associated variant rs12979860 [60279-7].
LOINC also contains nearly 50 codes for trinucleotide repeats,
including both qualitative tests with answers like not expanded,
intermediate, or expanded, and quantitative tests that report
the actual number of repeats, eg, HTT gene.CAG repeats
[53782-9].
Tests for chromosomal alterations
Many chromosomal alteration tests can also be reported as
computer-understandable observations using one or more
LOINC codes. For example, LOINC contains codes for qualitative
studies for trisomies and uniparental disomies, eg,
Chromosome 21 trisomy [Presence] [21771-1]. Today, aneu-
ploidy risk can also be estimated by quantifying the dosage of
chromosome-specific circulating cell-free DNA in maternal
plasma [see 73970-6], and such tests are revolutionizing pre-
natal testing.
A variety of LOINC codes are available for reporting struc-
tural chromosome rearrangements. For example, BCR-ABL1
testing for diagnosis and management of blood cell malignan-
cies is reported qualitatively as t(9;22)(q34.1;q11)(ABL1,BCR)
b2a2+b3a2 fusion transcript [42714-6]. The following 2
approaches exist for reporting the ratio of a BCR-ABL1 fusion
transcript to a control transcript: the raw transcript to control
ratio [e.g., 55147-3], and a transformed ratio based on an in-
ternational standard [e.g., 69380-4]. To increase computabil-
ity, tests that report a chromosomal alteration, such as BCR-
ABL1, should also report the results using the International
System for Human Cytogenetic Nomenclature (ISCN)30,31
when possible.
Fully structured reporting of molecular genetic and cytogenetic
tests
LOINC collaborated with HL7 to provide codes for all of the vari-
ables contained in two HL7 Clinical Genomics Working Group
implementation guides for structured reporting of genetic
tests—one for reporting genetic variations23 detected via
sequencing, gene chips, and other methods, and another for
reporting the results of cytogenetic studies.22 All of the LOINC
codes in these 2 implementation guides include guidance on
how they are to be used, and the categorical variables are
linked to specific sets of allowed answers.
The genetic variation collection consists of a number of
LOINC panels, including one that reports the overall results of
the study, another that reports the details about each variation
found, and yet another that describes the region of interest and
the gene chip as applicable (see figure 1). To improve the
integration of cytogenetic test results into EHRs, Heras et al18
examined a range of sample cytogenetic test names and result
reports and, from this empirical effort, created a LOINC-
enabled HL7 specification for reporting cytogenetic tests in a
fully structured form.22 The LOINC codes for this specification
are organized under the Chromosome analysis master panel
[62389-2], which includes a choice of subpanels for discrete
reporting of the 3 major testing approaches—chromosome
banding, fluorescence in situ hybridization, and microarrays.
Variables in this collection include the genomic source class
(eg, germline, somatic), genetic disease assessed, chromo-
some analysis in ISCN nomenclature, and overall interpretation
(for microarray example, see figure 2).
Mutation analysis tests
These HL7 definitions have not yet been adopted widely, how-
ever; and molecular genetic tests, especially those for large
numbers of variations, tend still to be reported as free-text nar-
rative.28 To accommodate this reality and provide a standard
way to order and report such tests, LOINC provides terms that
include the gene name(s) and phrase mutation analysis.
Currently LOINC distinguishes among the following different
types of mutation analyses:
1. Mutation analysis for a specific gene or genes that target a
fixed set of important mutations. Example: APC gene muta-
tion analysis [20990-8].
2. Mutation analysis limited to one or more known mutations
previously found in a family member. The mutations tested
vary by patient. Example: ACADVL gene mutation analysis
limited to known familial mutations [73736-1].
3. Full mutation analysis targeting the entire coding region in
the targeted part of the genome. Example: ACADVL full
gene mutation analysis . . . by sequencing [73735-3].
4. Mutation analyses for deletions/duplications. Example:
ACVRL1 gene + ENG gene deletion and duplication mutation
analysis [69481-9].
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Augmenting narrative reports
Because we anticipate the transition to a fully structured
molecular genomic reporting will take time, we encourage
services that report their content as narrative reports to also
include LOINC terms to deliver the core results in a computer-
understandable form. Specifically, for mutation analysis stud-
ies, we encourage the inclusion of one LOINC term that reports
the mutations found (eg, APC gene mutations found [20990-8])
and another that reports the mutations that could have been
found. For tests that report only a fixed set of mutations, this
can be done with 1 additional observation—APC gene muta-
tions tested for [21618-4]. For sequencing and other tests to
deliver the same information about what could have been
found, terms from the DNA region of interest panel [53041-0]
can be included as additional observations. All genetic studies
should also include an observation that reports the reference
sequence with a LOINC term such as Reference sequence
Identifier [48012-9].
Figure 1: Genetic analysis master panel.
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Cytogenetic tests that are delivered as narrative should
include an additional observation that provides the findings
in ISCN nomenclature to provide computability,30,31
eg, Chromosome analysis result in ISCN expression [62356-1].
However, it is better to provide the report in Heras’s full struc-
tured cytogenetic specification.18,22 Cytogenetic tests should
also include an observation for the reference assembly build
identifier such as Human reference sequence assembly release
number [62374-4].
Result values for LOINC genetic codes
The use of LOINC codes to identify genetic tests is 1 ingredient
for interoperability. Standards on the result values used to re-
port the variations detected are equally important. Full details
about the recommended result values for each code, ranging
from Systematized Nomenclature of Medicine–Clinical Terms
(International Health Standards Development Organization,
Copenhagen, Denmark) to HGVS syntax, are provided in the
LOINC database and in the HL7 implementation guides. In
Figure 2: Chromosome analysis microarray copy number change panel, included within the Chromosome analysis master
panel (62389-2) (not shown here).
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general, LOINC recommends the use of HGVS syntax for report-
ing variations and encourages the use of a second identifier,
such as NCBI’s dbSNP29 or ClinVar32 IDs or, in the case of so-
matic mutations on cancer specimens, COSMIC33 (Genome
Research Limited, Hinxton, UK) IDs. Since an HL7 Version 2
OBX-5 result field can carry 2 independent coding systems,
both the HGVS notation and an alternative identifier can be re-
ported together. For reporting pharmacogenomics genetic test
results, LOINC encourages the use of the star-allele nomencla-
ture34–36 as an additional way to report results because it is so
widely used. For cytogenetic studies, ISCN is the standard no-
menclature used to report genomic rearrangements identified
either by standard karyotyping or molecular methodologies.30
Mechanisms for contributing to LOINC content
Almost all of LOINC’s content is based on external requests from
laboratories, instrument vendors, test kit vendors, and public
health departments around the world. Regenstrief welcomes
requests for new LOINC terms. Submitters are asked to provide
information for each variable requested, including a proposed
LOINC name, a definition for the new analyte or method, units of
measure for quantitative variables, answer lists for categorical
variables, package inserts when a test is marketed, and deiden-
tified sample reports when needed to understand the structure
of test panels (see LOINC Users’ Guide37 for full details). Even
with this amount of information, the LOINC team invests time in
further research to enrich the definitions, verifying that existing
LOINC terms do not satisfy the request and ensuring consistency
across the database. The naming conventions in LOINC are
informed by the input we receive from requestors and volunteer
experts and are guided by the Laboratory LOINC Committee that
meets twice a year in open meetings.
LIMITATIONS AND CHALLENGES
LOINC has substantial coverage of existing laboratory tests, but
it is never complete. We hope to reach the point where we cre-
ate LOINC codes for all tests in their premarketing stage. We
are at that point for the test kits that the Centers for Disease
Control distributes externally and may reach the same point for
at least one large in vitro diagnostics vendor. LOINC lacks tests
for whole exome and whole genome testing, including some of
the newest whole genome microarray and high-resolution
comparative genomic hybridization tests,38 because we have
not yet received requests for them.
Variation in the styles for reporting genetic test results
poses a substantial challenge to standardization. For example,
some laboratories report variants identified on each
allele as separate variables (eg, Allele 1¼ TPMT*2,
Allele 2¼ TPMT*3C). Others report the value of both alleles as
a single variable with a 2-part answer (eg, TPMT*2/*3C). In
both cases, the allele naming style also varies considerably.
One laboratory may include both the gene name and the allele
name in the answer, another may report only the allele name,
and yet another may report wild type and the letter code for the
nucleotide result for the non–wild type. Further, some laborato-
ries may only report presence or absence of a specific variant.
We had discussions with the Food and Drug Administration
about determining 1 standard approach to report the value of 2
alleles and providing guidance to the laboratory kit and instru-
ment industry accordingly. They were open to this idea but
have not yet acted.
CONCLUSION
The need to integrate genetic data with EHRs is compelling.
LOINC is a widely adopted standard that provides codes to
improve interoperability of genetic test reporting, including fully
structured discrete reporting, tests for specific chromosomal
alterations or gene mutations, and narrative cytogenetic or
mutation analysis reports. By adopting and implementing data
standards like LOINC, information systems can help clinicians
unlock the potential of genetic information for delivering more
personalized care.
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